Company intelligence / Profile preview

AMYRA Biotech AG

Basel, Basel-Stadt, Switzerland

Ownership: Private
Employees: ~8
Development stage: Other

Overview

Successfully completed a first-in-human clinical proof-of-principle study with lead product AMYNOPEP, demonstrating enhanced digestion of proteolytically-resistant, immunogenic gluten peptides in healthy volunteers. Results published in Frontiers in Immunology – Nutritional Immunology in October 2024[7][9]

Therapeutic areas: Gastroenterology
Modalities: Enzyme-based therapeutics
Industry: Biotech

Drug pipeline

2 assets

BBEST02

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Lonza (development and manufacturing services agreement)[8]

Beyond the preview

Go deeper on AMYRA Biotech AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMYRA Biotech AG.

Explore the full profile